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ABSTRACT
p63 belongs to a family of transcription factors,
which, while demonstrating striking conservation of
functional domains, regulate distinct biological
functions. Its principal role is in the regulation
of epithelial commitment, differentiation and mainte-
nance programs, during embryogenesis and in adult
tissues. The p63 gene has a complex transcriptional
pattern, producing two subclasses of N-terminal
isoforms (TA and "N) which are alternatively
spliced at the C-terminus. Here, we report the iden-
tification of two new C-terminus p63 variants, we
named p63 d and e, that increase from 6 to 10 the
number of the p63 isoforms. Expression analysis of
all p63 variants demonstrates a tissue/cell-type-
specific nature of p63 alternative transcript expres-
sion, probably related to their different cellular
functions. We demonstrate that the new p63
variants as "N isoforms are active as transcription
factors as they have nuclear localization and can
modulate the expression of p63 target genes.
Moreover, we report that, like "Np63a, "Np63d and
e sustain cellular proliferation and that their expres-
sion decreases during keratinocyte differentiation,
suggesting their involvement in this process. Taken
together, our results demonstrate the existence of
novel p63 proteins whose expression should be
considered in future studies on the roles of p63 in
the regulation of cellular functions.
INTRODUCTION
p63 is a member of a family of transcription factors, also
including the tumor suppressor p53 and p73, which show
high level identity in their main functional domains: the
transactivation domain (TA), the DNA-binding domain
(DBD) and the oligomerization domain (OD).
The human p63 gene, like the p53 and p73 genes,
produces multiple protein isoforms as a result of alterna-
tive promoter usage and alternative splicing events (1).
The promoter upstream of exon 1 generates the class of
the TAp63 isoforms containing the TA at the N-terminus,
while an alternative promoter in intron 3 leads to
the expression of the Np63 isoforms lacking the
N-terminal TA domain, although it has been shown that
the Np63 isoforms can act as regulators of transcription
through diﬀerent TAs present in the distinct N-terminus
(2) and C-terminus regions (3). Within each subclass,
C-terminal alternative splicing events confer additional
complexity. To date, three variants, a, b and g, which
incorporate diﬀerent portions of the C-terminus, have
been described. The a proteins are the longest including
all terminal exons and containing the C-terminal sterile
alpha motif (SAM) domain—a protein–protein inter-
action domain, followed by an inhibitory domain (TI),
which is able to auto-inhibit the transcriptional activity
of the TA subclass isoforms (4). The b variants lack
exon 13 and consequently the SAM and the TI domains.
The g variants lack the C-terminal exons 11, 12, 13, 14, but
incorporate an additional sequence of unknown func-
tion from intron 10. Therefore, the p63 gene expresses at
least six diﬀerent p63 isoforms (TAp63 a, b, g and Np63
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in their structural domains and transcriptional activities.
Despite the structural conservation between members of
the p53 family, they are not functionally redundant as
p53-family transgenic knockout mice develop distinct
phenotypes, indicating that each protein has speciﬁc
biological functions. Several lines of evidence suggest
that, while the main role of p53 is related to the
inhibition of tumor progression, p73 and p63 appear
to be more directly involved in development and diﬀeren-
tiation (5–7).
Current data indicate that p63 is an essential mediator
of embryonic development. p63
 /  mice have no
epidermis and other stratiﬁed epithelia and also show
striking defects in limb development (6). TA and Np63
isoforms are expressed during distinct stages of embryonic
epidermal development. TAp63 isoforms are the ﬁrst p63
isoforms to be expressed during embryonic development
and they are necessary for the commitment to epithelial
stratiﬁcation while simultaneously blocking diﬀerentiation
program. Therefore, a shift towards Np63 isoforms
during later stages would be required to counterbalance
the activity of TAp63, thereby allowing cells to respond to
terminal diﬀerentiation cues (8,9). In adults, the Np63a
isoform is predominantly expressed in the basal layers
of stratiﬁed epithelial tissues, suggesting that it may
contribute to maintain the proliferative potential of
basal cells necessary for the epithelial stratiﬁcation
(10,11). In human p63, germline mutations have been
reported in patients with ectodermal dysplasia syn-
dromes, showing varying degrees of craniofacial, limb,
skin and hair defects which resemble the phenotype of
p63
–/  mice (12).
The role of p63 in tumorigenesis is controversial.
Initially, p63 was hypothesized to function as oncosup-
pressor based on its homology to p53. Mutations in the
p63 gene are quite rare in human cancers and the gene
maps in a region of chromosome 3 frequently ampliﬁed
in squamous cell carcinoma. In primary head and neck
squamous cell tumors and in other squamous epithelial
cancers, Np63a is over-expressed and it was suggested
that this form is required to maintain a stem cell-like
state, allowing continuous proliferation and promoting
tumor growth (13). Recently, it has been reported that
p63
+/  mice show a predisposition towards squamous
cell carcinoma and that loss of p63 can cooperate with
loss of p53 in tumor development, as dual heterozygous
p63
+/  and p53
+/  mice display higher tumor burden and
metastasis,comparedtop53
+/ mice(14).Onthecontrary,
another independent study reported that p63
+/  mice
show no evidence of enhanced tumor development and
that dual heterozygous p63
+/  and p53
+/  mice display
reduced tumor burden compared to p53
+/  mice (15).
In order to investigate the expression of the p63 gene,
we have applied a bioinformatics approach (16,17), which
detects transcript variants through the multiple alignment
of all available transcript and/or EST sequences of a gene
to the corresponding genomic sequence. Here we describe
the identiﬁcation of two novel human p63 C-terminal
variants, that we have named d and e; we describe the
in vivo validation of these new p63 variants, and present
results regarding their functional characterization.
MATERIALS AND METHODS
Bioinformatics
Novel p63 variants were identiﬁed using ASPicDB
(10) (http://www.caspur.it/ASPicDB/index.php), which
provided access to reliable annotations of the alternative
transcriptional pattern of all human genes. AspicDB was
used to obtain sequence data of every transcript and
protein isoform predicted, and also to identify intron/
exon boundaries of the genomic sequence corresponding to
each variant, essential for the design of isoform-speciﬁc
primer sets. Sequence data were aligned using Clustalw2
(http://www.ebi.ac.uk/Tools/clustalw2/index.html).
Cell cultures, transfection and in vitro keratinocyte
differentiation
H1299, MCF-7, 293 and HaCat cell lines were maintained
in Dulbecco’s modiﬁed Eagle’s Medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), L-glutamine
(2mM), penicillin (100U/ml) and streptomycin (100mg/
ml) at 378C, 5% CO2. Transfections were carried out
with Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. Eight micrograms of either
empty pcDNA3 vector or vector containing the diﬀerent
Np63 variants (a, b, g, d and e) were used for a 60mm
plate of H1299 and MCF-7 cells (90–95% conﬂuency).
Cells were cultured in DMEM plus serum without
antibiotics for 24h. Then the medium was replaced with
fresh complete medium and the cells were cultured for
additional 24h.
Normal human epidermal Keratinocytes were isolated
from neonatal foreskin specimens derived from a normal
human Caucasian (PromoCell). Cells were maintained in
Stemline
TM Keratinocyte Medium II (Sigma) supple-
mented with 1  Keratinocyte medium supplement, BPE
free, L-glutamine (2mM), penicillin (100 U/ml) and strep-
tomycin (100mg/ml) at 378C, 5% CO2. Keratinocytes were
diﬀerentiated by adding CaCl2 (2mM ﬁnal concentration)
and reducing the supplement, BPE free, to 0.1  for 24
and 48h.
Cell proliferation assay by BrdU incorporation
MCF-7 cells were transfected with 100ng of either empty
pcDNA3 vector (control) or containing p53 or the
diﬀerent Np63 variants (a, b, g, d and e). Seventy-two
hours later, bromodeoxyuridine (BrdU) incorporation,
after 3h pulses was determined by using Cell Proliferation
ELISA BrdU (Roche) as described by the manufacturer.
Reverse transcriptase polymerase chain reaction and
quantitative RT–PCR analyses
Total RNA from HaCat, H1299, MCF-7, 293 and
primary keratinocyte cell lines was extracted using
RNeasy Plus Mini Kit (Qiagen) according to the manu-
facturer’s instructions. Total RNA from human muscle
and brain was purchased from commercial sources
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RNA using QuantiTect Reverse Transcription kit
(Qiagen).
For Reverse transcriptase polymerase chain reaction
(RT–PCR) experiments, 1ml of cDNA was used as
template for ampliﬁcations carried out with speciﬁc
primer sets. The sequences of all primers are available
upon request. PCR was run in the exponential region to
allow semi-quantitative comparisons among cDNAs
developed from identical reactions.
For quantitative RT–PCR, 1ml of cDNA was used as
template in real-time PCR assays, performed in triplicate
on ABI PRISM 7900HT (Applied Biosystems). Each p63
variant was analyzed using the QuantiTect SYBR Green
PCR Master Mix (Qiagen) with validated speciﬁc primers
pairs. The PCR conditions were designed as follows: hot
start at 958C for 15min; 45 cycles of ampliﬁcation (948C
for 15s, 628C for 30s, 728C for 30s); dissociation curve
step (958C for 15s, 608C for 15s, 958C for 15s). For the
quantiﬁcation of ada, fasn, redd1, bax, p21, k14 and k1
transcripts, real-time PCR assays were performed using
the TaqMan Universal PCR Master Mix (Applied
Biosystems) with speciﬁc TaqMan Gene Expression
Assays (Applied Biosystems) as described by the
manufacturer.
Results were analyzed with the SDS 2.2.1 software. The
comparative threshold (Ct) method was used to determine
the relative ratio of transcripts. The relative quantiﬁcation
(RQ) was expressed as 2
–Ct, where Ct was calculated
as the average Ct for target variant minus the average Ct
of endogenous gapdh in each sample, and Ct was
calculated as the Ct of the sample minus the Ct of
the calibrator. The data shown are the average from at
least three independent experiments.
Construction of recombinant vectors
The full-length coding region of the human Np63d and
Np63e variants was ampliﬁed from HaCat cDNAs using
the Platinum Taq DNA Polymerase High Fidelity
(Invitrogen) and cloned into SacII/ApaI sites of a
pcDNA3 expression vector containing the laminin A
50UTR downstream the CMV promoter. The resulting
vectors were termed pcDNA3-Np63d and pcDNA3-
Np63e.
Western blot analysis
For protein analysis, cells were washed twice in cold PBS
and then lysed in RIPA buﬀer [50mM Tris–HCl pH 7.5,
150mM NaCl, 1% Nonidet P40, 0.5% sodium deoxy-
cholat, 0.1% SDS, protease inhibitors cocktail tablets
(Roche)] for 1h on ice. Lysates were then cleared by
centrifugation at 10000g for 15min at 48C, aliquoted
and stored at –208C. Sixty micrograms of the total
proteins, in 4  SDS–PAGE sample buﬀer, were heated
at 1008C for 5min, separated on 4–12% SDS polyacry-
lamide gels and transferred to nitrocellulose membranes
(Hybond-ECL, Amersham Biosciences). Membranes
were then blocked for 1h in a PBS solution containing
3% non-fat milk powder and 0.1% Tween-20, and then
probed at room temperature with Abp63 (4A4, Santa
Cruz) for 3h, in 3% milk, 0.1% Tween-20 PBS. For the
analysis of keratinocyte diﬀerentiation, membranes were
probed also with the following primary antibodies: Abp53
(DO-1, Santa Cruz) for 3h, Abp21 (Calbiochem) for 3h,
Ab-actin (Calbiochem) for 1h. After two 10min washes in
0.1% Tween-20 PBS and one 10min wash in PBS,
proteins were visualized using ECL western blotting
detection reagents (Amersham Pharmacia Biotech).
Luciferase assays
H1299 cells were plated in 35mm tissue culture dishes
(8 10
4cells/dish) 24h before transfection. Each well
was then co-transfected using TransIT-LT1 Transfection
Reagent (Mirus Bio), according to the manufacturer’s
instructions, with either empty pcDNA3 vector or
containing the diﬀerent Np63 variants (150ng), the
reporter vector (1mg) along with Renilla pRL-SV40
vector (Promega) (10ng).
Thirty-six hours after transfection, H1299 were lysed in
Passive Lysis buﬀer (Promega) and the luciferase assay
was performed using the Dual Luciferase assay system
(Promega), according to the manufacturer’s instructions.
Data were normalized to the Renilla reporter signal.
The results reported represent the average of at least
three independent experiments and are shown with the
standard deviations.
Immunofluorescence
H1299 cells were plated on a glass coverslip polylisine
treated in six-well plates (4 10
4cells/well). Twenty-four
hours later, cells were transfected using TransIT-LT1
Transfection Reagent (Mirus Bio), with either empty
pcDNA3 vector or containing the diﬀerent Np63
variants (1mg). Thirty-six hours after transfection, cells
were ﬁxed and permeabilized for 30min with cold 50%
methanol–50% acetone and then incubated at room tem-
perature for 90min with the Abp63 (4A4, Santa Cruz) at
1:50 dilution in DMEM plus serum. For cells transfected
with empty pcDNA3 vector, only DMEM plus serum was
added. After extensive washing, cells were incubated for
1h at room temperature in the dark with FITC-
conjugated secondary Ab against mouse Ig (Jackson) in
DMEM plus serum (1:100). Nuclei were stained with
DAPI (0.2mg/ml). Fluorescence was analyzed with
Axioplan 2 Imaging microscope (Zeiss).
RESULTS
In silico identification of two novel human p63 variants
Through the application of ASPIC, an algorithm for
the prediction of alternative transcripts (16,17), we
investigated the transcriptional pattern of the human
p63 gene. Among the p63 transcripts predicted by the
software, which included known isoforms, we detected
two previously unidentiﬁed C-terminus p63 variants. The
ﬁrst variant, herein referred to as d, derives from the
skipping of exons 12 and 13; the second variant, referred
to as e, is generated by a premature transcriptional termi-
nation in intron 10, retaining the 50 portion of intron 10,
6094 Nucleic Acids Research, 2009, Vol. 37,No. 18which immediately presents a stop codon (Figure 1A). The
nucleotide sequences of the Np63 d and e transcripts
were deposited in GenBank, with the accession numbers
GQ202690 and GQ202689, respectively.
The d and e transcripts produce proteins with diﬀerent
C-terminal regions (Figure 1B). In particular, the d
proteins contain 53/101 residues of the second TA
(TA2), followed by eight unique amino acids after the
oligomerization domain (OD). The e proteins are the
shortest isoforms, lack the TA2 domain and terminate,
after the OD, with 22 amino acids shared with a, b and
d isoforms; the g proteins also lack the TA2 domain,
maintain 21 common residues and terminate with 38
unique amino acids. The alignment among the
C-terminal regions of d and e p63 proteins and the
known a, b and g forms is reported in Figure 1C.
In vivo identification of d and e p63 isoforms in
keratinocytes
To conﬁrm the in vivo expression of the new d and e p63
isoforms, we used two human keratinocyte cell lines,
HaCat and Nhek, as it is known that N isoforms of
p63 are highly expressed in these cells (1). We performed
RT–PCR experiments and western blotting analysis in
order to validate both the new p63 transcripts and
proteins.
RT–PCR experiments were carried out on total
RNA using primer pairs speciﬁcally designed for the
ampliﬁcation of each variant, as shown in Figure 2.
Ampliﬁcation with primers For-ex11 and Rev-ex14
produced a 385bp amplicon corresponding to that
expected for the new d transcript as well as 624 and
530bp amplicons expected for the a and b transcripts,
respectively (Figure 2A). To identify the e transcripts
we used primers For-ex7 and Rev-ex100 producing only
one amplicon, whose size of about 620bp corresponded
to that expected for the e transcripts (Figure 2B). All
amplicons were subcloned into a PCR cloning vector
and sequenced. Alignment of the d and e amplicon
sequences to the p63 gene sequence conﬁrmed the
in silico prediction of the new p63 transcripts exactly
(data not shown).
Figure 1. Human p63 gene. (A) Schematic representation of human p63 gene structure: alternative promoters (P1 and P2), previously identiﬁed
alternative splicing events (a, b and g) and novel events (d and e) are indicated. (B) Np63 protein isoforms are reported with their molecular size.
TA1
 :T Ao fN isoforms; DBD: DNA-binding domain; OD: oligomerization domain; TA2: C-terminal TA; SAM: sterile alpha motif; TI:
inhibitory domain. (C) Amino acid alignment among the C-terminal regions of d and e p63 proteins and the known a, b and g.
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class in keratinocytes, we also ampliﬁed and sequenced
the entire coding region of Np63d and Np63e
transcripts from HaCat and Nhek cDNAs. Analysis of
sequences conﬁrmed the presence of these new Np63
transcripts.
Next, we analyzed expression of Np63 proteins in
human keratinocytes and in a human breast carcinoma
cell line. Lysates from HaCat and MCF-7 cells were
resolved on a 4–12% SDS/PAGE gel together with size
standard controls for each Np63 isoform (Np63a, b, g,
d and e). These standards were prepared by transfecting
H1299 cells (which don’t express detectable p63 protein)
with pcDNA3 vectors expressing the cDNAs of each
Np63 isoform. Western analysis was performed using a
pan-p63 antibody that recognizes the core DBD of p63.
As shown in Figure 3, after a long exposure, HaCat and
MCF-7 cell lysates revealed two bands corresponding to
the Np63d and e isoforms in addition to the known
Np63 proteins. Moreover, diﬀerential expression of the
Np63 isoforms was observed. Indeed, in HaCat cells
Np63g, d and e present lower levels of expression than
Np63b and in particular Np63a, which is the predom-
inant isoform, while in MCF-7 cells, Np63d seems to
be the least expressed p63 isoform.
Expression of p63 transcripts in normal tissues and
cell lines
In order to quantify the relative amounts of all p63
transcripts in diﬀerent human tissues and cell lines and
to determine their tissue-speciﬁcity, we performed real
time RT–PCR assays.
Since p63 transcripts diﬀer only in the 30 end of their
coding region, we were not able to construct primers/
Figure 2. In vivo identiﬁcation of novel p63 d and e transcripts. (A) RT–PCR analysis of HaCat and Nhek RNAs which identiﬁes the a, b and d
transcripts; on the right, a schematic representation of the portion of p63 transcripts ampliﬁed with the expected size. (B) RT–PCR analysis from
HaCat and Nhek RNAs which identiﬁes the e transcripts; on the right, a schematic representation of the portion of p63 transcripts ampliﬁed with the
expected size. Primers used are indicated by arrows.
Figure 3. Identiﬁcation of the novel Np63d and e proteins.
Endogenous p63 protein expression was evaluated by western analysis
in HaCat and MCF-7 cells. Five micrograms of lysate of H1299 over-
expressing Np63a, b, g, d and e proteins were used as molecular
marker to assess an identity to each Np63 isoform in 60mgo f
Hacat and MCF-7 lysates. The pan-p63 4A4 antibody was used to
detect Np63 isoforms. Ectopically expressed Np63a, b and g show
a higher molecular mass than expected as they express the myc-tag in
their N-terminus. Arrows on the right indicate the position of Np63d
and e isoforms in HaCat and MCF-7 lysate. The molecular weights of
protein markers are shown on the left.
6096 Nucleic Acids Research, 2009, Vol. 37,No. 18probe sets for each variant. For this reason, we used the
SYBR Green chemistry, designing speciﬁc primer pairs,
mapping in the limited diﬀerent sequence, to distinctly
amplify each p63 variant (a, b, g, d and e). In addition,
to distinguish between the TA and Np63 transcript
subclasses, we designed primer pairs able to amplify only
the 50 end of TA and N transcripts.
Total RNA from primary muscle, brain and
keratinocyte samples, embryonic kidney 293, breast
cancer MCF-7 and HaCat cell lines was analyzed. First,
we compared the relative levels of the TA and N p63
transcripts in each sample, using TA transcripts as
calibrators (Figure 4A). Among tissues studied, only
primary keratinocytes express high levels of N
transcripts ( 200-fold more than TAs), while muscle
and brain show no detectable levels of N transcripts.
We could thus consider the TA class as the predominant
one in these samples. Among cell lines, HaCat cells exhibit
the highest levels of N transcripts ( 400-fold more than
TAs); in the MCF-7 cells, N transcripts are  2-fold
more expressed than TA, while no detectable levels of
Np63 mRNAs were observed in 293 cell line.
Next, we assessed the relative levels of each p63 variant
(a, b, g, d and e) in each sample examined, using the a
variant, which is generally the most expressed variant, as
calibrator (Figure 4B). The proﬁle of the TA and N p63
transcripts in these samples allowed us to associate the
expression values obtained for each variant, to either TA
or N subclasses. Results obtained, indicated that the
new d and e p63 variants are expressed in all samples
examined and, overall, all p63 variants show diﬀerences
in their expression pattern. In fact, among tissues, the a
variant is the most expressed in all samples, with the
exception of muscle, in which the g variant showed the
highest expression level. Interestingly, we found that in
muscle, apart from the g and a variants the e variant is
the most highly expressed, while b and d variants are
almost undetectable. In brain, we found that, after the
a variant, the e variant is more highly expressed than
the g, b and d variants, the latter being the least
expressed in this tissue. Among cell lines, the a variant,
is also the most highly expressed in all samples. HaCat
cells showed an expression pattern similar to that of
primary keratinocytes, with g, d and e variants relatively
less expressed than a and b variants. In 293 cells, e and
d variants showed a higher expression level than b and
g variants, while in MCF-7 cells, after the b, the g and e
variants showed higher expression levels than the d
variant, in accord with observed protein expression
levels (see Figure 3).
Figure 4. Expression proﬁle of human p63 transcripts in diﬀerent normal tissues and cell lines. (A) TA and N p63 transcripts levels were quantiﬁed
by qRT–PCR. Values are expressed as fold change respect to TA transcripts, used as calibrator, after internal normalization for gapdh expression
(see ‘Material and Methods’ section). (B) p63 a, b, g, d and e mRNA levels were quantiﬁed by qRT–PCR. Values are expressed as fold change
respect to a variant, used as calibrator, after internal normalization to gapdh expression.
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variant among the tissues and cell lines examined
(Figure 5). Among tissues, we observed that a, b and d
variants are more expressed in keratinocytes than in
muscle and brain, while, interestingly, the g and e
variants present the highest levels in muscle tissue (respec-
tively, 8- and 4-fold more expressed than in keratinocytes).
Very low levels of all p63 variants are present in brain
respect to the other tissues (Figure 5A). Among cell
lines, HaCat cells show much higher expression levels of
all ﬁve variants than MCF-7 and especially 293 cells
(>9-fold expression drop) (Figure 5B).
Nuclear localization of "Np63d and "Np63e isoforms
For the functional characterization of the new p63d and e
variants, we focused our attention on the N isoforms.
Given that the p63 gene encodes transcription factors, we
investigated whether Np63d and Np63e proteins show
nuclear localization. The Np63d or Np63e complete
coding region was cloned in the pcDNA3 expression
vector and the recombinant vectors were transfected in
H1299 cells which were immunostained using the p63
4A4 antibody and a FITC-conjugated secondary antibody.
Empty pcDNA3 vector was used as negative control,
while cells transfected with vectors expressing Np63a,
Np63b and Np63g were used as positive controls.
The subcellular distribution of all Np63 isoforms
was assessed by ﬂuorescence microscopy. As shown in
Figure 6, we found that the ectopic expression of
Np63d and Np63e isoforms led to an exclusively
nuclear localization of ﬂuorescence, suggesting that these
variants, showing nuclear localization, could act as tran-
scription factors and modulate the expression of p63
target genes. Identical cellular localization was, as
expected, observed for the Np63a, Np63b and
Np63g proteins, used as controls.
Transactivation activity of "Np63d and "Np63e isoforms
towards some p53 family target genes
In order to demonstrate that Np63d and Np63e
proteins have transcriptional activity, we performed lucif-
erase assays, to assess whether they are able to directly
activate some p53 family responsive promoters (fasn,
ada, bax and p21) (18–21). To this end, diﬀerent
luciferase constructs—pGL3promoter-fasn, pGL3pro
moter-ada, pGL3basic-bax and pGL3basic-p21—were
co-transfected into p53 null H1299 cells either with a
pcDNA3 empty vector as control or with the pcDNA3
vectors expressing Np63d and Np63e and the known
Np63 isoforms (a, b, g), to compare the activity of all
Np63 isoforms. In parallel, for each assay, the
intracellular level of transfected proteins was assessed by
western blot.
As shown in Figure 7A, we found that Np63d and
Np63e have signiﬁcant transcriptional activity towards
fasn RE, with 7- and 6-fold activation, respectively,
compared with the control, although Np63a and b are
the strongest transactivating variants on this element, with
21- and 18-fold activation of the target, respectively. The
remaining variant, Np63g, shows similar levels of target
activation to Np63e. Considering that Np63b and g
show the lowest expression levels, the transactivation
activity of these two isoforms could be even greater than
that evaluated.
Regarding the ada RE (Figure 7B), we found that
Np63d and e show transactivation activity similar to
that of Np63a and b, with an increase of the luciferase
activity of about 7-fold for Np63d and of about 5.5-fold
for Np63e, compared with the control. Weaker trans-
activation activity is showed by Np63g, which induced
only 3-fold activation of the target. As Np63a and
Np63e transfected proteins have higher expression
levels than other isoforms, their transactivation activity
could be slightly lower than that estimated.
The activation of the bax RE is also diﬀerentially
modulated by the Np63 isoforms (Figure 7C).
We found that Np63d and Np63e activate the bax
RE, with an increase of the luciferase activity of about
8-fold for Np63d and of about 10-fold for Np63e,
like Np63a, while Np63b and Np63g transactivate
this element more eﬃciently, with an increase of about
53-fold and 39-fold, respectively, with respect to the
control.
Finally, Figure 7D shows the transcriptional activity
of the Np63 isoforms on the p21 RE. Np63d and
Np63e, do not show relevant transcriptional activity
on the p21 promoter, as already observed for Np63a
(2). In agreement with other groups (2,3), we found that
Figure 5. Diﬀerential expression of human p63 transcripts among diﬀerent normal tissues (A) and cell lines (B). mRNA levels of p63 variants (a, b,
g, d and e) were quantiﬁed by qRT–PCR. Values are expressed as fold change respect to keratinocytes and HaCat cells, used as calibrators,
respectively for tissues and cell lines, after internal normalization to gapdh expression.
6098 Nucleic Acids Research, 2009, Vol. 37,No. 18Np63b and Np63g are able to activate the p21 RE,
with an increase of about 9- and 4-fold activation of the
target, respectively.
Taken together, these results indicated that the new
Np63 isoforms, Np63d and Np63e, show a signiﬁ-
cant transactivation activity towards the p63 REs
examined, except for p21 and that the Np63 isoforms
diﬀer in their regulatory activity on the p63 REs.
Effect of "Np63d and "Np63e isoforms over-expression
on p63 target gene expression and cellular proliferation
To determine whether the new Np63 variants are able to
modulate the endogenous expression of p63 target genes,
we performed quantitative RT–PCR to detect the mRNA
levels of some Np63 positive (fasn, ada, redd1 and p21)
and negative (bax, C/EBPdelta and igfbp-3) genes (18–24)
in the presence of over-expression of the ﬁve Np63
isoforms in H1299 and MCF-7 cell lines (Figure 8A and
B). The levels of exogenously expressed Np63 isoforms
in H1299 and MCF-7 cells were monitored by western
blot analysis (Figure S1). We found that, in both cell
lines, fasn, ada and redd1 genes appear to be upregulated,
to varying degrees, by Np63d and Np63e as well as by
the other isoforms (with the exception of redd1 which is
downregulated by Np63a in H1299 cells). In particular,
in H1299 cells, Np63 e increases the levels of fasn
Figure 6. Nuclear localization of Np63d and Np63e isoforms. H1299 cells were transiently transfected for 24h with individual vectors expressing
the novel Np63d and e isoforms and Np63a, b and g isoforms as controls, and immunostained using the p63 4A4 antibody and a FITC-
conjugated secondary antibody. Nuclei were counterstained with DAPI.
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Np63d determines the highest increase of ada mRNA
levels. The p21 expression is upregulated by Np63b
and slightly by Np63d and Np63e in H1299 cells, in
accordance with luciferase assay results, while no p21
activation by all isoforms is detected in MCF-7, as
previously reported for Np63a and Np63g (2). In
both cell lines, bax expression is downregulated by all
Np63 isoforms, suggesting that, in conditions of over-
expression, the Np63 isoforms repress the expression of
the pro-apoptotic bax gene in accordance with their
known antiapoptotic role (25). This result is in contrast
with the luciferase results, but could be due to the artiﬁcial
nature of the luciferase construct. In both cell lines, the
other two negative target genes C/EBPdelta and igfbp-3
are downregulated by Np63d and Np63e while,
interestingly, igfbp-3 appears to be upregulated by
Np63b. These results demonstrate that Np63d and
Np63e, like the other Np63 isoforms, are able to
modulate in vivo the expression of Np63 target genes
and that this modulation varies in the two cellular
contexts.
On the basis of previous data and in order to assess
whether Np63 isoforms aﬀect cellular proliferation, we
compared MCF-7 cells over-expressing Np63 isoforms
with wild-type cells, by BrdU incorporation (Figure 8C).
The levels of exogenously expressed Np63 isoforms in
MCF7 cell line were monitored by western blot analysis
(data not shown). Interestingly, the ectopic expression
of the Np63a, Np63d and e isoforms, but not of p53
and Np63b and g isoforms, increased cell proliferation
rate to diﬀerent degrees: Np63a showing a higher
eﬃcacy than Np63d and e. These data demonstrate
that Np63d and e isoforms, like Np63a, have eﬀects
distinct from those of Np63b, Np63g and p53 on the
cell cycle and that their over-expression increases cell
proliferation rate.
Expression of "Np63d and "Np63e isoforms during
keratinocyte differentiation
It has been reported that Np63a expression is modulated
during keratinocyte diﬀerentiation; being required to
maintain the proliferative potential of basal cells of
the epidermis but being down-regulated in terminally
diﬀerentiated cells in more luminal strata (8). We
investigated the expression of the new Np63d and
Np63e isoforms during keratinocyte diﬀerentiation, by
analyzing the expression pattern of all Np63 isoforms
in diﬀerentiating keratinocyte cells, used as a model
of squamous epithelium. To induce diﬀerentiation of
proliferating keratinocytes, we altered the extracellular
Ca
2+ concentration from 0mM to 2mM and the
medium serum concentration from 1  to 0.1 . The
expression of the Np63 isoforms was analyzed at 24
and 48h following the diﬀerentiation stimulus.
Figure 7. Np63d and Np63e isoforms have transactivation activity. H1299 cells were transiently co-transfected with the pcDNA3 empty vector or
expressing Np63 a, b, g, d and e and the reporter constructs pGL3-fasnRE (A), pGL3-adaRE (B), pGL3-baxRE (C) and pGL3-p21RE (D). The
fold increase in relative luciferase activity was calculated using the empty pcDNA3 vector as control. The results represent the average of at least
three independent experiments and are shown with the standard deviations. For each reporter construct, the expression level of the Np63 isoforms
was checked by western blotting.
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primer pair sets able to amplify the full-length Np63
transcripts, and qRT–PCR analysis (Figure 9B) of
Np63 variants showed a progressive reduction of the
levels of all Np63 transcripts, in particular, at 48h
after the diﬀerentiation stimulus. Figure 9C shows the
Np63 protein pattern during the diﬀerentiation process
which is similar to that of the transcripts, as a reduction of
all Np63 isoforms is observed, such that, only Np63a
remains detectable 48h after the diﬀerentiation stimulus.
As controls for the diﬀerentiation induction, we ﬁrst
monitored the levels of p21 and p53 proteins, involved
in cell cycle block. As shown in Figure 9D, at 24
and 48h after the diﬀerentiation stimulus, p21 levels
and especially p53 levels increased, with respect to
proliferating cells.
Moreover, we analyzed the transcript levels of keratin
14 and keratin 1, two keratinocyte diﬀerentiation markers,
to conﬁrm the proper diﬀerentiation status of Nhek cells
(Figure 9E). We found a remarkable progressive increase
of keratin 1 mRNA and a decrease, more evident at 48h,
of the transcript of keratin 14, a marker of the less
diﬀerentiated layers of epidermis, which is also positively
regulated by Np63 (26). In addition, we examined the
expression of other Np63-regulated genes (ada, redd1,
keratin 4) (Figure 9E). Consistent with the reduction
of all Np63 isoforms during diﬀerentiation, we also
observed a relative decrease of transcripts of ada and
redd1 target genes and an increase of keratin 4
expression, which was reported to be downregulated by
Np63 (27).
DISCUSSION
The p63 gene, along with p53 and p73, belongs to the p53
gene family. Although their products show some common
structural and functional features, each protein seems
to have speciﬁc biological functions. In fact, while
p53-deﬁcient mice grow normally but undergo spontane-
ous tumor development, p73 and p63 knockout mice
exhibit severe developmental and diﬀerentiation defects
(6,7,28). A common feature of the three genes is to
produce a great variety of isoforms, either derived from
the use of an internal cryptic promoter or by alternative
splicing, giving rise to a network of proteins whose ﬁne
modulation is fundamental in the regulation of biological
activities, ranging from development and diﬀerentiation to
growth arrest and apoptosis (29). The p63 gene generates
Figure 8. Ectopic expression of Np63d and Np63e isoforms aﬀects the in vivo expression of p63 target genes and promotes cellular proliferation.
H1299 (A) and MCF-7 (B) cell lines were transfected with the pcDNA3 vector or vector expressing Np63 a, b, g, d and e and harvested after 48h.
mRNA levels of fasn, ada, redd1, p21, bax, C/EBPdelta and igfbp-3 genes were quantiﬁed by qRT–PCR. Values are expressed as percentage of fold
change respect to the control (pcDNA3), after internal normalization to gapdh expression. (C) Bromodeoxyuridine (BrdU) incorporation after 3h
pulses by MCF-7 cells transfected with pcDNA3 control vector, or with the indicated expression vectors.
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those containing the TA, called TA isoforms, and those
lacking this domain, called N isoforms. Moreover, three
alternative splicing events have been identiﬁed, producing
the a, b and g, variants, which incorporate various
portions of the C-terminus, for both TA and Np63
isoforms.
Therefore, until now six diﬀerent p63 isoforms (TAp63
a, b, g and Np63 a, b, g) have been identiﬁed, with a
complex array of similarities and diﬀerences in their
structural domains and transcriptional activities.
By using the ASPIC algorithm (16,17), a tool for alter-
native splicing prediction, based on multiple transcripts
and/or EST sequence comparison and alignment against
the gene sequence, we identiﬁed two new human p63
C-terminus variants, one we named d, deriving from an
alternative splicing event between exons 11 and 14, and
the other, we deﬁned e, that keeps the 50 portion of intron
10, which immediately presents a stop codon. Transcript
isoforms homologous to the e and d variants were not
detected for p73 gene. The ASPIC algorithm, unlike
other alternative splicing prediction methods which
perform independent single transcript alignments with
the genomic region, carries out an optimized alignment
of all the gene-related transcripts with the aim of
minimizing the number of predicted splice sites and
consequently of the relevant transcript variants. The relia-
bility of the ASPIC algorithm along with the signiﬁcant
number of EST sequences supporting these new p63
variants, prompted us to investigate the presence of
these new p63 proteins in vivo.
Here, ﬁrst we identiﬁed these new p63 variants in
keratinocytes and MCF-7 cells, indicating that the
ASPIC algorithm could be considered to provide valid
starting point in the search for transcriptional variants
of genes of interest (Figures 2 and 3). In keratinocytes,
known to express high levels of p63 as N variants, we
observed a diﬀerential expression of the novel variants
with respect to the other known isoforms. In particular,
Np63d is highly expressed respect to Np63g and
Np63e and, as expected, the Na and b variants are
the predominant isoforms (Figure 4B).
We extended the study of the expression of all ﬁve p63
variants, by qRT–PCR methodology, to diﬀerent normal
human tissues and cell lines in order to determine whether
it was tissue-speciﬁc (Figure 4). The results conﬁrmed that
the p63 variants are diﬀerentially expressed, either as TA
and N form, in tested samples and that the two new
variants, d and e, show interesting expression proﬁles.
In brain, where only the TA class was detected, the e
variant is the most expressed after the a variant, and in
muscle tissue, the TAp63e transcript shows levels only
slightly lower than TAp63a. Among the cell lines
analyzed, HaCat cells show a p63 expression proﬁle
similar to keratinocytes, while in MCF-7 cells, e variants
show similar expression level to b and g variants, while d
variants show the lowest expression. Interestingly, in 293
cells, the e and d variants seem to be the predominant
Figure 9. Expression of Np63d and Np63e isoforms is modulated during keratinocyte diﬀerentiation. Diﬀerentiation of proliferating
keratinocytes was induced by varying the extracellular Ca
2+ concentration from 0 to 2mM and the medium serum concentration from 1  to
0.1  for 24 and 48h. (A) RT–PCR analysis of full-length Np63 mRNA levels in proliferating keratinocytes (–Ca
2+) and at 24 and 48h after Ca
2+
addition. (B) qRT–PCR analyses of Np63 variants in proliferating keratinocytes (–Ca
2+) and at 24h and 48h after Ca
2+ addition. Values are
expressed as fold change respect to the control (–Ca
2+) after internal normalization to gapdh expression. (C) Western blotting analysis of all Np63
proteins in proliferating keratinocytes (–Ca
2+) and at 24 and 48h after Ca
2+ addition. Ectopically expressed Np63 proteins were used as molecular
marker to assess an identity to each Np63 isoform. The pan-p63 4A4 antibody was used to detect p63 isoforms. L.E.=long exposure, S.E.=short
exposure. (D) Western blotting analysis of p21 and p53, used as controls of the diﬀerentiation induction. (E) qRT–PCR analysis of ada, redd1,
keratin 4, keratin 14 and keratin 1 mRNA levels during keratinocyte diﬀerentiation. Values are expressed as fold induction respect to the control
(–Ca
2+), after internal normalization to gapdh expression.
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each p63 variant among the tissues and cell lines
(Figure 5), showing that a, b and d variants are more
expressed in keratinocytes, while g and e variants are
present at higher levels in muscle tissue. Very low levels
of all p63 variants are present in brain with respect to the
other tissues analyzed. Among cell lines, very low
expression of all variants were observed in MCF-7 and
293 cells with respect to HaCat cells.
After demonstrating the in vivo expression of the new d
and e p63 variants, we have performed initial functional
characterization. An indication that, like other isoforms,
Np63d and Np63e act as transcription factors, was
derived from the study of their cellular localization and
transactivation activity. In fact, both Np63d and
Np63e show a nuclear localization (Figure 6), have sig-
niﬁcant transactivation activity towards the p63 REs
examined (Figure 7) and are able to regulate in vivo the
expression of Np63 positive and negative target genes
although with diﬀerent eﬃciency with respect to the
other Np63 isoforms (Figure 8A and B). The eﬀect of
the ectopic expression of the Np63 isoforms on the
expression of the target genes is variable in the two
cellular contexts examined, suggesting that other cell-
speciﬁc transcription factors may participate with
Np63 proteins in the regulation of these genes.
Moreover, we show that the ectopic expression of the
Np63d and e isoforms, like Np63a, increase the cell
proliferation rate, while Np63b, Np63g and p53
reduce proliferation rates (Figure 8C). Taken together,
these data may suggest that Np63d and e isoforms, as
Np63a, could have a role in sustaining cell proliferation
as they activate genes involved in cell cycle progression
(fasn and ada) but not the pro-apoptotic gene bax.
The d and e p63 proteins lack one of the two TAs
(TA2), which was demonstrated to be required for the
transcriptional activity of the N isoforms (3). Overall,
our results demonstrate that the N forms of these
variants are functionally active, suggesting that the TA
(TA1
 ) (2) present at the N-terminus of all N isoforms
contributes signiﬁcantly to their transcriptional activity.
Moreover, we studied the expression proﬁle of the new
Np63 variants during keratinocyte diﬀerentiation. Many
studies report a role for p63 in the diﬀerentiation of
epidermis, a key process by which the epithelial cells
acquire their proper morphological and functional
properties (30). However, it remains unclear how exactly
this takes place. The basal compartment of stratiﬁed
epithelia is made of cells with high proliferative capacity
that replenish the terminally diﬀerentiated populations
in the more luminal strata. Np63a is the isoform
predominantly expressed in this basal compartment
while TA isoforms are not detectable. It is suggested
that Np63a is required to maintain the proliferative
potential of basal cells and to allow the initial induction
of keratinocyte diﬀerentiation, while it must be down-
regulated to allow terminal diﬀerentiation (9).
Our results conﬁrm that the diﬀerentiation process
is associated with lower levels of all Np63 isoforms
(Figure 9) not only Np63a, at both the transcripts and
protein levels, although their relative abundance seems
to be maintained. Moreover, during diﬀerentiation, we
observed a reduction of the expression of some known
Np63 target genes, consistent with the reduction of
the Np63 variants, supporting the hypothesis that all
isoforms, including Np63d and Np63e, could, along
with Np63a, play a pro-proliferative role in this physi-
ological condition. Further studies to deﬁne the signals
controlling the balance in the expression of all the p63
isoforms will help to better understand the contribution
of p63 to proper epidermal homeostasis.
Taken together, our results demonstrate the existence of
new p63 variants, which are functionally active as tran-
scription factors, increasing to 10 the number of the
isoforms that are produced by the p63 gene.
The implications of this study open interesting avenues
for future investigation. In particular, we have
demonstrated tissue/cell type-speciﬁc expression of p63
alternative transcripts, suggesting possible relationships
to their diﬀerent cellular function. A better understanding
of the regulation of expression of all p63 possible variants
will thus be essential for meaningful p63 functional
studies. Indeed, future studies on p63 function should
take into account the possible presence of these new
variants in the tissue or cell type examined, which if
ignored would provide partial and/or potentially
incorrect results.
Furthermore, the existence of new p63 variants
increases the known complexity of the crosstalk among
all the p53 family members and of their mutual
regulation in the maintenance of the proper cellular
growth of epithelial tissues.
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